科伦博泰生物-B(06990)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06990 科伦博泰生物-B

休市中 12-05 16:09:08

460.000

+11.000

+2.45%

最高462.600	最低447.400	成交量37.90万
今开449.000	昨收449.000	日振幅3.39%
总市值1,073亿	流通市值748.74亿	总股本2.33亿
成交额1.73亿	换手率0.23%	流通股本1.63亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06990","market":"HK","secType":"STK","nameCN":"科伦博泰生物-B","latestPrice":460,"timestamp":1764922148008,"preClose":449,"halted":0,"volume":379048,"delay":0,"floatShares":162769979,"shares":233185969,"eps":-1.3255611466139363,"marketStatus":"休市中","change":11,"latestTime":"12-05 16:09:08","open":449,"high":462.6,"low":447.4,"amount":173240252,"amplitude":0.033853,"askPrice":460,"askSize":23900,"bidPrice":457.8,"bidSize":300,"shortable":3,"etf":0,"ttmEps":-3.526722922936793,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765157400000},"marketStatusCode":7,"adr":0,"listingDate":1689004800000,"exchange":"SEHK","adjPreClose":449,"openAndCloseTimeList":[[1764898200000,1764907200000],[1764910800000,1764921600000]],"volumeRatio":1.2424479220889608,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06990","defaultTab":"news","newsList":[{"id":"2589853098","title":"智通港股早知道 | 因大宗商品供应线路被扰乱 航运价格飙升467%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589853098","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589853098?lang=zh_cn&edition=full","pubTime":"2025-12-05 07:27","pubTimestamp":1764890871,"startTime":"0","endTime":"0","summary":"航运价格飙升467% 因大宗商品供应线路被扰乱12月3日，波罗的海干散货指数报2845点，创下2023年12月6日以来新高水平，单日涨幅达9.42%，为近两个月最大单日涨幅。四位知情人士透露，摩科瑞已于12月2日取消了仓单，预定提取LME存放在亚洲仓库中的、超过4万吨铜金属。受让方与转让方于2025年12月4日分别签署收购合同。收购事项完成后，标的公司将成为本公司的间接非全资附属公司，而其财务业绩将综合计入本公司的财务报表。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377951.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0196878994.USD","06990","000979.SH","02676","161715","BK1161"],"gpt_icon":0},{"id":"2588088622","title":"科伦博泰生物-B(06990)与Crescent Biopharma建立战略合作伙伴关系，共同开发和商业化肿瘤治疗手段","url":"https://stock-news.laohu8.com/highlight/detail?id=2588088622","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588088622?lang=zh_cn&edition=full","pubTime":"2025-12-04 19:43","pubTimestamp":1764848616,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦博泰生物-B 公布，公司与Crescent Biopharma,Inc.及其全资子公司Crescent Biopharma Operating Company,LLC已建立战略合作伙伴关系，共同开发和商业化肿瘤治疗手段。Crescent则授予公司在大中华地区研究、开发、生产和商业化CR-001的独家权利。此次合作包括开发两款候选药物的单药疗法，以及评估CR-001与SKB105的联用疗法。若Crescent近期发生控制权变更或与第三方签订分许可协议，公司亦有资格向Crescent收取额外款项。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377830.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","LU0196878994.USD","06990","LU0329678170.USD","LU0329678337.USD","LU0737861772.HKD","LU2488822045.USD","06078","BK1161","BK1209"],"gpt_icon":0},{"id":"1114300938","title":"科伦博泰生物-B公司将获得8000万美元的预付款及高达12.5亿美元的里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1114300938","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114300938?lang=zh_cn&edition=full","pubTime":"2025-12-04 19:36","pubTimestamp":1764848173,"startTime":"0","endTime":"0","summary":"科伦博泰生物-B公司将获得8000万美元的预付款及高达12.5亿美元的里程碑付款。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0196878994.USD","BK1161","06990"],"gpt_icon":0},{"id":"1115537632","title":"Crescent Biopharma Inc - 将获得2000万美元的预付款，以及来自科伦博泰生物的最高3000万美元的额外里程碑款项","url":"https://stock-news.laohu8.com/highlight/detail?id=1115537632","media":"美股速递","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115537632?lang=zh_cn&edition=full","pubTime":"2025-12-04 19:32","pubTimestamp":1764847944,"startTime":"0","endTime":"0","summary":"Crescent Biopharma Inc - 将获得2000万美元的预付款，以及来自科伦博泰生物的最高3000万美元的额外里程碑款项","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1064130708.USD","LU1979443071.USD","BK0060","06990","BK4139","CBIO","002422","LU2148510915.USD","LU1064131003.USD","BK0239","LU0196878994.USD","BK1161","LU1934453819.USD"],"gpt_icon":0},{"id":"1126942018","title":"Crescent Biopharma Inc - 科伦博泰生物-B将获得8000万美元的预付款，以及来自Crescent的最高达12.5亿美元的额外里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1126942018","media":"美股速递","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126942018?lang=zh_cn&edition=full","pubTime":"2025-12-04 19:32","pubTimestamp":1764847941,"startTime":"0","endTime":"0","summary":"Crescent Biopharma Inc - 科伦博泰生物-B将获得8000万美元的预付款，以及来自Crescent的最高达12.5亿美元的额外里程碑付款","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","06990","LU0196878994.USD","002422","LU1064131003.USD","LU1934453819.USD","BK0239","BK1161","CBIO","LU1064130708.USD","LU2148510915.USD","LU1979443071.USD","BK0060"],"gpt_icon":0},{"id":"1115079280","title":"科伦药业与Crescent Biopharma达成战略合作，共同开发及商业化新型抗肿瘤疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1115079280","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115079280?lang=zh_cn&edition=full","pubTime":"2025-12-04 19:30","pubTimestamp":1764847815,"startTime":"0","endTime":"0","summary":"科伦药业与Crescent Biopharma达成战略合作，共同开发及商业化新型抗肿瘤疗法","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["002422","06990","BK0239","LU0196878994.USD","LU1064130708.USD","BK1161","CBIO","LU1064131003.USD","BK4139","LU2148510915.USD","LU1934453819.USD","BK0060","LU1979443071.USD"],"gpt_icon":0},{"id":"2588074906","title":"医药股普遍回暖 荣昌生物(09995)涨4.26% 交银国际料明年内地医药板块稳中向好态势延续","url":"https://stock-news.laohu8.com/highlight/detail?id=2588074906","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588074906?lang=zh_cn&edition=full","pubTime":"2025-12-04 10:58","pubTimestamp":1764817092,"startTime":"0","endTime":"0","summary":"金吾财讯 | 医药股普遍回暖，荣昌生物 涨4.26%，康方生物涨3.89%，金斯瑞生物科技涨3.11%，康诺亚-B涨2.95%，科伦博泰生物-B涨2.45%，诺诚健华涨1.79%，药明生物涨1.63%，泰格医药涨1.38%，药明康德涨1.33% 。交银国际发表报告指，予内地医药行业领先评级。如该行此前预期，内地医药行业2025年迎来关键转折。2026年，该行认为板块稳中向好态势延续，但影响市场表现的核心因素或呈分化态势。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250110/NmI5OTlmYjAxY2FmOGFlNWZkYjg2NDM0MTE4MzUwMDcw.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/NmI5OTlmYjAxY2FmOGFlNWZkYjg2NDM0MTE4MzUwMDcw.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1970883","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0588546209.SGD","LU0516422952.EUR","IE00BPRC5H50.USD","09926","LU0819121731.USD","03329","HK0000320264.USD","LU2399975544.HKD","LU0634319403.HKD","BK1610","LU1720050803.USD","688331","LU2242644610.SGD","LU0359201612.USD","LU0516423091.SGD","LU2148510915.USD","LU0181495838.USD","02162","BK1574","LU0823426308.USD","LU1688375341.USD","LU1961090484.USD","LU0856984785.SGD","09969","LU2039709279.SGD","BK0239","LU2488822045.USD","BK1589","LU0561508036.HKD","02269","159938","LU0052750758.USD","BK1141","LU0359202008.SGD","BK1587","09939","LU1880383366.USD","02359","06990","LU0326950275.SGD","03347","09995","BK1161","LU0307460666.USD","01548","LU2328871848.SGD","LU2476274720.SGD","LU0417516571.SGD","LU1046422090.SGD","BK1515"],"gpt_icon":0},{"id":"2588403227","title":"每日卖空追踪 | 科伦博泰生物-B 12月02日卖空量成交3.96万股，卖空比例为14.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588403227","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588403227?lang=zh_cn&edition=full","pubTime":"2025-12-02 16:30","pubTimestamp":1764664235,"startTime":"0","endTime":"0","summary":"科伦博泰生物-B北京时间12月02日，跌0.41%，卖空量成交3.96万股，较上一交易日减少77.9%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251202163608978b6656&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251202163608978b6656&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06990","BK1161","LU0196878994.USD"],"gpt_icon":0},{"id":"2587475778","title":"科伦博泰公布TROP2 ADC治疗尿路上皮癌2期临床结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2587475778","media":"医药地理","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2587475778?lang=zh_cn&edition=full","pubTime":"2025-11-29 15:48","pubTimestamp":1764402539,"startTime":"0","endTime":"0","summary":"11月28日，科伦博泰自主研发的TROP2 ADC芦康沙妥珠单抗单药治疗晚期或转移性尿路上皮癌患者的临床研究数据荣登国际知名学术期刊Annals of Oncology。这项研究首次证实了芦康沙妥珠单抗在治疗晚期尿路上皮癌患者中可取得显著临床获益的潜力。此次期刊发表基于一项评估芦康沙妥珠单抗单药治疗经化疗和免疫检查点抑制剂治疗进展的晚期或转移性尿路上皮癌疗效及安全性的Ⅱ期临床研究队列9的结果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251129155121a7190857&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251129155121a7190857&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","06990","LU0196878994.USD"],"gpt_icon":0},{"id":"2587736189","title":"每日卖空追踪 | 科伦博泰生物-B 11月28日卖空量成交3.5万股，卖空比例为15.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2587736189","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2587736189?lang=zh_cn&edition=full","pubTime":"2025-11-28 16:30","pubTimestamp":1764318635,"startTime":"0","endTime":"0","summary":"科伦博泰生物-B北京时间11月28日，跌0.13%，卖空量成交3.5万股，较上一交易日减少72.83%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251128164715951f5fa8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251128164715951f5fa8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0196878994.USD","06990","BK1161"],"gpt_icon":0},{"id":"2586227686","title":"每日卖空追踪 | 科伦博泰生物-B 11月27日卖空量成交6.75万股，卖空比例为21.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586227686","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586227686?lang=zh_cn&edition=full","pubTime":"2025-11-27 16:30","pubTimestamp":1764232233,"startTime":"0","endTime":"0","summary":"科伦博泰生物-B北京时间11月27日，涨0.88%，卖空量成交6.75万股，较上一交易日减少28.42%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251127163836951d5985&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251127163836951d5985&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","06990","LU0196878994.USD"],"gpt_icon":0},{"id":"2586290451","title":"中信证券：给予科伦博泰生物-B(06990)目标价592港元 维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2586290451","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586290451?lang=zh_cn&edition=full","pubTime":"2025-11-27 10:34","pubTimestamp":1764210896,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中信证券发布研报称，科伦博泰生物-B核心产品芦康沙妥珠单抗已获得MNC认可和全球开发能力的加持，同时结合默沙东K药进一步拓展ADC+IO联用可能性，考虑到核心产品全球开发进程加速推进，国内商业化放量在即，结合DCF估值测算，给予公司目标价592港元，维持“买入”评级。该结果进一步验证了芦康沙妥珠单抗的联合治疗潜力，叠加其已获批的3项适应症及多项在研临床，管线价值持续兑现。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1374293.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06990"],"gpt_icon":0},{"id":"2586213375","title":"科伦博泰生物-B盘中异动 大幅拉升3.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586213375","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586213375?lang=zh_cn&edition=full","pubTime":"2025-11-27 10:07","pubTimestamp":1764209252,"startTime":"0","endTime":"0","summary":"2025年11月27日早盘10时07分，科伦博泰生物-B股票出现异动，股价快速上涨3.13%。科伦博泰生物-B股票所在的生物技术行业中，整体跌幅为0.74%。基于预期2026年多项催化剂的出现，摩根大通将科伦博泰生物列为中国生物医药板块中的首选标的。摩根大通认为，科伦博泰生物在中国生物医药领域具有重要地位，并预计其将在未来几年持续受益于创新药物的研发和商业化进程。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251127100732951cba34&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251127100732951cba34&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0196878994.USD","06990","BK1161"],"gpt_icon":0},{"id":"2586260666","title":"研报点睛：涨幅居前！关注这一赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2586260666","media":"东方财富研究中心","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586260666?lang=zh_cn&edition=full","pubTime":"2025-11-26 17:35","pubTimestamp":1764149725,"startTime":"0","endTime":"0","summary":"11月26日，A股三大指数今日涨跌不一，截止收盘，沪指跌0.15%，收报3864.18点；深证成指涨1.02%，收报12907.83点；创业板指涨2.14%，收报3044.69点。国金证券表示，CGT 等前沿创新，或迎监管更多支持；数据生态新赛道，隐藏未来新金矿。颠覆性创新技术赛道的布局，将是未来药企制胜要地。新一代技术的细胞基因疗法、AI制药等前沿赛道，或是2026年新热点。医药医疗数据要素相关企业，值得药企布局和资本市场关注与投资。国泰海通表示，持续推荐创新药械及产业链。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251126174028a4bb8740&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251126174028a4bb8740&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02359","LU0359202008.SGD","BK1191","06990","02615","LU1023057109.AUD","01276","LU0359201612.USD","LU2543165471.USD","06160","03347","LU0359201885.HKD"],"gpt_icon":0},{"id":"2586298011","title":"科伦博泰生物－Ｂ升目标价至545港元，重申“增持”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2586298011","media":"摩根大通","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586298011?lang=zh_cn&edition=full","pubTime":"2025-11-26 16:15","pubTimestamp":1764144950,"startTime":"0","endTime":"0","summary":"同时，该行重申了对该公司的“增持”评级。此外，作为中国生物医药板块的首选标的，科伦博泰生物的表现值得投资者密切关注。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251126163120a71282c0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251126163120a71282c0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06990","BK1161","LU0196878994.USD"],"gpt_icon":0},{"id":"2586287292","title":"每日卖空追踪 | 科伦博泰生物-B 11月25日卖空量成交14.96万股，卖空比例为23.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586287292","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586287292?lang=zh_cn&edition=full","pubTime":"2025-11-25 16:30","pubTimestamp":1764059435,"startTime":"0","endTime":"0","summary":"科伦博泰生物-B北京时间11月25日，跌0.44%，卖空量成交14.96万股，较上一交易日减少65.77%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251125163551a4b8feec&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251125163551a4b8feec&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0196878994.USD","06990","BK1161"],"gpt_icon":0},{"id":"2586728725","title":"科伦博泰生物-B11月25日主力净流出368.3万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2586728725","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586728725?lang=zh_cn&edition=full","pubTime":"2025-11-25 16:15","pubTimestamp":1764058535,"startTime":"0","endTime":"0","summary":"11月25日, 科伦博泰生物-B股价跌0.44%，报收448.20元，成交金额2.9亿元，换手率0.39%，振幅6.53%，量比1.49。科伦博泰生物-B今日主力资金净流出368.3万元，上一交易日主力净流入216.5万元。该股近5个交易日上涨2.99%，主力资金累计净流入1023.8万元，其中2个交易日为股价下跌时净流入；近20日主力资金累计净流入7057.3万元，其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025112516181395192411&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025112516181395192411&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","LU0196878994.USD","06990"],"gpt_icon":0},{"id":"2586472874","title":"小摩：升科伦博泰生物-B(06990)目标价至545港元 重申“增持”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2586472874","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586472874?lang=zh_cn&edition=full","pubTime":"2025-11-25 15:32","pubTimestamp":1764055931,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，摩根大通发布研报称，对科伦博泰生物-B的看法更为积极，将其2025至2033年的收入预测上调1%至10%，目标价由499港元上调至545港元。因预期2026年有多项催化剂出现，该行持续将公司列为中国生物医药板块中的首选标的，重申“增持”评级。公司日前公布有关SKB264的内地第三期临床试验的数据，反映正面进展。基于结果，公司计划在国内提交sac-TMT针对有关适应症的补充新药申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1373221.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06990"],"gpt_icon":0},{"id":"2586872382","title":"成都温江：两家药企上榜“中国创新力企业50强”","url":"https://stock-news.laohu8.com/highlight/detail?id=2586872382","media":"中国经济时报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586872382?lang=zh_cn&edition=full","pubTime":"2025-11-25 14:22","pubTimestamp":1764051769,"startTime":"0","endTime":"0","summary":"图片来源/温江区投资促进局■中国经济时报记者王彩娜 ■韩清华 张丽近日，福布斯中国发布“2025中国创新力企业50强”榜单，全国共有8家医药企业入选，其中，温江两家企业百利天恒和科伦博泰上榜。据了解，科伦博泰积极融入行业趋势，与默沙东等全球制药公司深度合作，充分嫁接全球资源，高效兑现创新价值，成为中国药企全球化创新的标杆。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251125142705a4b8b8d3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251125142705a4b8b8d3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","LU0196878994.USD","02615","06990"],"gpt_icon":0},{"id":"2586872152","title":"科伦博泰TROP2 ADC III期临床达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2586872152","media":"药视声Medispace","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586872152?lang=zh_cn&edition=full","pubTime":"2025-11-25 13:05","pubTimestamp":1764047101,"startTime":"0","endTime":"0","summary":"11月24日，科伦博泰宣布，其自主研发的TROP2 ADC芦康沙妥珠单抗(佳泰莱)联合帕博利珠单抗一线治疗PD-L1阳性非小细胞肺癌的III期临床研究，在预设的无进展生存期期中分析中，经独立数据监查委员会确认已达到主要终点，显示出统计学意义和临床意义的显著改善，并在总生存期方面观察到获益趋势。这是首个ADC联合免疫检查点抑制剂在一线治疗NSCLC上达到主要终点的III期临床研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251125151232a70ff960&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251125151232a70ff960&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0196878994.USD","06990","BK1161"],"gpt_icon":0}],"profile":{"websiteUrl":"http://kelun-biotech.com","stockEarnings":[{"period":"1week","weight":0.0079},{"period":"1month","weight":0.0594},{"period":"3month","weight":-0.1221},{"period":"6month","weight":0.3593},{"period":"1year","weight":1.4798},{"period":"ytd","weight":1.8169}],"compareEarnings":[{"period":"1week","weight":0.0087},{"period":"1month","weight":0.0058},{"period":"3month","weight":0.0262},{"period":"6month","weight":0.0964},{"period":"1year","weight":0.3336},{"period":"ytd","weight":0.3004}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"四川科伦博泰生物医药股份有限公司是一家主要从事新药业务的研发、生产和销售的中国公司。该公司主要从事肿瘤学、免疫学及其他治疗领域的创新药物的研发、制造及商业化。该公司的产品为抗体药物偶联物（ADC）SKB264及A166。该公司产品主要用于乳腺癌、非小细胞肺癌、胃肠道癌等非肿瘤疾病的治疗。","exchange":"SEHK","name":"科伦博泰生物-B","nameEN":"SKB BIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"科伦博泰生物-B(06990)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供科伦博泰生物-B(06990)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"科伦博泰生物-B,06990,科伦博泰生物-B股票,科伦博泰生物-B股票老虎,科伦博泰生物-B股票老虎国际,科伦博泰生物-B行情,科伦博泰生物-B股票行情,科伦博泰生物-B股价,科伦博泰生物-B股市,科伦博泰生物-B股票价格,科伦博泰生物-B股票交易,科伦博泰生物-B股票购买,科伦博泰生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"科伦博泰生物-B(06990)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供科伦博泰生物-B(06990)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}